Amgen Inc. (AMG.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
As of 03:41PM CEST. Market open.
| Previous close | 277.20 |
| Open | 277.85 |
| Bid | 279.60 x 20000 |
| Ask | 280.05 x 9000 |
| Day's range | 277.85 - 279.75 |
| 52-week range | 196.60 - 306.00 |
| Volume | |
| Avg. volume | 618 |
| Market cap | 150.505B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 42.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.29 (2.99%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Bloomberg
Investors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeJudge Threatens Trump With Jail Over Gag Order ViolationsTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s
- Simply Wall St.
Amgen First Quarter 2024 Earnings: EPS Misses Expectations
Amgen ( NASDAQ:AMGN ) First Quarter 2024 Results Key Financial Results Revenue: US$7.45b (up 22% from 1Q 2023). Net...
- GuruFocus.com
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
Insightful Analysis of Amgen Inc's Strengths, Weaknesses, Opportunities, and Threats
© 2024 Yahoo. All rights reserved.